Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evidence-based cerebral vasospasm management.

George W Weyer1, Colum P Nolan, R Loch Macdonald

  • 1Section of Neurosurgery, Department of Surgery, University of Chicago Medical Center and Pritzker School of Medicine, Chicago, Illinois, USA.

Neurosurgical Focus
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Everybody Complains about Vasospasm but Nobody Does Anything about It.

Neurocritical care·2026
Same author

Prognostication Following Aneurysmal Subarachnoid Hemorrhage: The Modified Hunt and Hess Grading Scale.

Stroke (Hoboken, N.J.)·2026
Same author

Phase 1, randomized, crossover study comparing intravenous GTX-104 to oral nimodipine in healthy human subjects.

PloS one·2025
Same author

Probing our understanding of intracranial aneurysms.

The Lancet. Neurology·2025
Same author

Microvascular Decompression of the Medulla: A Case Report and Review of the Surgical Management.

Cureus·2025
Same author

In Reply: Blood Pressure Targets After Aneurysmal Subarachnoid Hemorrhage: Is Lower Better?

Neurosurgery·2025
Same journal

Letter to the Editor. Enhancing comparability in idiopathic intracranial hypertension research through standardized outcome measures.

Neurosurgical focus·2026
Same journal

Introduction. Contemporary spinal arthroplasty.

Neurosurgical focus·2026
Same journal

Cervical disc arthroplasty as a safe and effective procedure for obese patients.

Neurosurgical focus·2026
Same journal

Comparing the operational metrics and functional outcomes of lumbar arthroplasty implants: a systematic review.

Neurosurgical focus·2026
Same journal

Long-term reoperation risk after cervical disc arthroplasty versus fusion: a level-matched meta-analysis of FDA investigational device exemption studies and international randomized trials.

Neurosurgical focus·2026
Same journal

Total disc replacement versus lumbar interbody fusion for degenerative disc disease: a meta-analysis of randomized controlled trials.

Neurosurgical focus·2026
See all related articles

Nimodipine is the only proven therapy for cerebral vasospasm following subarachnoid hemorrhage (SAH). Other treatments show limited or inconclusive efficacy, highlighting the need for improved clinical trials and further research into alternative therapies.

Area of Science:

  • Neurology
  • Neurosurgery
  • Clinical Pharmacology

Background:

  • Cerebral vasospasm and delayed cerebral ischemia are frequent, serious complications after aneurysmal subarachnoid hemorrhage (SAH).
  • Current therapeutic options for cerebral vasospasm are limited, with only calcium antagonists demonstrating strong evidence of effectiveness.

Purpose of the Study:

  • To systematically review the existing literature on therapies for the prevention and treatment of cerebral vasospasm and delayed cerebral ischemia following SAH.

Main Methods:

  • A comprehensive literature search was conducted to identify randomized controlled trials (RCTs) evaluating various therapeutic interventions.
  • Forty-one articles met the inclusion criteria for the systematic review, and their study characteristics and primary outcomes were analyzed.

Related Experiment Videos

Main Results:

  • Nimodipine is the only therapy with proven efficacy for vasospasm after SAH; tirilazad was found to be ineffective.
  • Studies on hemodynamic maneuvers, magnesium, statins, endothelin antagonists, steroids, anticoagulants/antiplatelets, and intrathecal fibrinolytic drugs yielded inconclusive results.
  • The overall quality of clinical trials in this field was initially poor but has shown significant improvement over time.

Conclusions:

  • Nimodipine is indicated for patients following SAH, while tirilazad is not recommended.
  • Further research is warranted for hemodynamic maneuvers, other calcium channel blockers (e.g., nicardipine), magnesium, statins, endothelin antagonists, and intrathecal fibrinolytic therapy.
  • Investigating rescue therapies like balloon angioplasty and intra-arterial vasodilators presents challenges, and improving the quality of future clinical trials is crucial.